1.北京中医药大学,北京市朝阳区北三环东路11号,100029
2.中日友好医院
Email:lilinxcy@126.com
收稿:2021-11-21,
修回:2022-03-30,
纸质出版:2022-08-02
移动端阅览
王子涵,张瑾,兰天仪等.基于Markov模型的中西医结合治疗心力衰竭远期疗效评价研究[J].中医杂志,2022,63(15):1449-1455.
WANG Zihan,ZHANG Jin,LAN Tianyi,et al.Evaluation of Long-term Effect of Integrated Traditional Chinese and Western Medicine on Heart Failure based on Markov Model[J].Journal of Traditional Chinese Medicine,2022,63(15):1449-1455.
王子涵,张瑾,兰天仪等.基于Markov模型的中西医结合治疗心力衰竭远期疗效评价研究[J].中医杂志,2022,63(15):1449-1455. DOI: 10.13288/j.11-2166/r.2022.15.010.
WANG Zihan,ZHANG Jin,LAN Tianyi,et al.Evaluation of Long-term Effect of Integrated Traditional Chinese and Western Medicine on Heart Failure based on Markov Model[J].Journal of Traditional Chinese Medicine,2022,63(15):1449-1455. DOI: 10.13288/j.11-2166/r.2022.15.010.
目的
2
应用马尔科夫(Markov)模型评价中西医结合治疗对心力衰竭患者远期临床结局的影响,探讨Markov模型在心力衰竭领域的适用性。
方法
2
通过中日友好医院病历系统进行回顾性的信息检索,筛选2016年7月至2021年1月就诊于中日友好医院中西医结合心内科的心力衰竭住院患者。共纳入符合标准的心力衰竭患者161例,根据治疗方式将其分为常规西药治疗组67例和中西医结合治疗组94例。记录患者一般资料、实验室指标及心功能指标,以6个月为1个周期评估患者出院后心功能分级变化情况,并记录有无复合心血管事件发生。依据真实随访数据构建Markov模型,预测队列患者治疗1、3、5年后心功能情况及最终健康效用值,并与真实情况比较验证模型真实性。
结果
2
中西医结合治疗组患者年龄相对常规西药治疗组更大(
P
=0.019)。以Markov模型模拟1、3、5年的疾病发展,预测中西医结合治疗组发生心血管事件概率分别为4.8%、6.0%、6.2%,估计健康效用值分别为0.161、0.167、0.083;常规西药治疗组发生心血管事件概率分别为14.4%、21.5%、24.3%,估计健康效用值分别为0.126、0.117、0.057;中西医结合治疗组患者整体心功能水平优于常规西药治疗组,且各时点心血管事件发生率均更低(
P
<0.001)。治疗1年时心功能的模型预测频率与实际随访频率比较,常规西药治疗组(
P
=0.351)与中西医结合治疗组(
P
=0.077)差异均无统计学意义。
结论
2
中西医结合治疗相比于常规西药治疗心力衰竭具有更好的远期临床疗效,Markov模型可较好适用于心力衰竭领域。
Objective
2
To evaluate the long-term effect of integrated traditional Chinese and western medicine on the clinical outcomes of heart failure(HF)patients using Markov model,and to explore the applicability of Markov model in the field of HD.
Methods
2
The clinical data of HF inpatients in the department of integrated traditional Chinese and western medicine in China-Japan Friendship Hospital from July 2016 to January 2021 was retrospectively collected through the medical record system of the hospital. A total of 161 patients with HF who met the criteria wereincluded,and were divided into 67 patients in the conventional(western medicine)treatment group and 94 patients in the integrated(traditional Chinese and western medicine)treatment group according to the treatment received. The general information,laboratory indicators and cardiac function indicators were recorded,while the changes of cardiac function grade after discharge were evaluated every six months,and the occurrence of composite cardiovascular events was recorded. Markov models were constructed based on real follow-up data to predict the 1y-,3y- and 5y- cardiac function and final health state utility values(HSUVs),and to verify the authenticity of the models compared with the real condition.
Results
2
Relatively older patients were found in the integrated treatment group than the conventional treatment group(P=0. 019). Using a Markov model to simulate 1y-,3y- and 5y-disease progression,the corresponding occurrence rates of cardiovascular events were predicted to be 4. 8%,6. 0%,and 6. 2%,and the HSUVs were0. 161,0. 167,and 0. 083 in the integrated treatment group,while those were 14. 4%,21. 5%,and 24. 3%,and 0. 126,0. 117,and 0. 057 in the conventional treatment group. Patients in the integrated treatment group had better overall cardiac function and a lower incidence of cardiovascular events at all time points than those in the conventional treatment group(P<0. 001). Comparing the model-predicted frequency of cardiac function with the actual frequency of follow-up at one year of treatment,there was no statistically significant difference between the conventional treatment group(P=0. 351)and the integrated treatment group(P=0. 077)
Conclusion
2
Integrated traditional Chinese and western medicine has a better long-term effect on HF compared with conventional western medicine therapy,andMarkov model can be used in the field of HF.
YANCY CW , JESSUP M , BOZKURT B , et al . 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America [J]. Circulation , 2017 , 136 ( 6 ): e137 - e161 .
滑莹莹 , 张晓明 . 强心利水通脉汤治疗慢性心力衰竭利尿剂抵抗的临床研究 [J]. 中华中医药杂志 , 2020 , 35 ( 8 ): 4235 - 4238 .
刘倩茹 , 王新陆 , 朱明军 , 等 . 参附益心颗粒对AngⅡ诱导的H9c2心肌细胞损伤及PGC-1α信号通路相关因子的影响 [J]. 中医杂志 , 2022 , 63 ( 7 ): 679 - 687 .
来晓磊 , 尚菊菊 , 刘红旭 , 等 . 泻肺利水合剂联合西医常规方法治疗慢性缺血性心力衰竭气虚血瘀证疗效的真实世界、多中心、队列研究 [J]. 中医杂志 , 2022 , 63 ( 6 ): 544 - 550 .
SONNENBERG FA , BECK JR . Markov models in medical decision making: a practical guide [J]. Med Decis Making , 1993 , 13 ( 4 ): 322 - 338 .
BALA MV , MAUSKOPF JA . Optimal assignment of treatments to health states using a Markov decision model: An introduction to basic concepts [J]. Pharmacoeconomics , 2006 , 24 ( 4 ): 345 - 354 .
陶涛 , 周英 , 戴玲燕 , 等 . 采用多状态Markov模型分析我国老年人失能转移规律 [J]. 中国全科医学 , 2019 , 22 ( 10 ): 1165 - 1170 .
李奕贵 , 梁金连 , 谢世旋 . 基于Markov模型急性非ST段抬高型心肌梗死介入治疗与药物保守治疗的药物经济学评价 [J]. 中国药物经济学 , 2018 , 13 ( 3 ): 5 - 12 .
PONIKOWSKI P , VOORS AA , ANKER SD , et al . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [J]. Rev Esp Cardiol (Engl Ed) , 2016 , 69 ( 12 ): 1167 .
中华医学会心血管病学分会心力衰竭学组 , 中国医师协会心力衰竭专业委员会 , 中华心血管病杂志编辑委员会 . 中国心力衰竭诊断和治疗指南2018 [J]. 中华心血管病杂志 , 2018 , 46 ( 10 ): 760 - 789 .
SAHN DJ , DEMARIA A , KISSLO J , et al . Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements [J]. Circulation , 1978 , 58 ( 6 ): 1072 - 1083 .
王强 , 王承龙 , 王少丽 . Markov模型在中医药防治心力衰竭临床研究中的应用 [J]. 中医杂志 , 2018 , 59 ( 8 ): 659 - 662 .
THOMPSON AJ , TURNER AJ . A Comparison of the EQ-5D-3L and EQ-5D-5L [J]. Pharmacoeconomics , 2020 , 38 ( 6 ): 575 - 591 .
BECK JR , PAUKER SG . The Markov process in medical prognosis [J]. Med Decis Making , 1983 , 3 ( 4 ): 419 - 458 .
YAO Y , ZHANG R , AN T , et al . Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China [J]. ESC Heart Fail , 2020 , 7 ( 6 ): 3582 - 3592 .
吴晶 , 黄泰康 . 马尔科夫模型及其在药品经济预测中的应用 [J]. 中国药房 , 2005 , 16 ( 14 ): 1049 - 1050 .
马兴录 , 杨文文 , 冯云霞 . 心血管疾病风险评估研究综述 [J]. 计算机应用 , 2018 , 38 ( z2 ): 111 - 114 .
LINDBOHM JV , SIPILÄ PN , MARS NJ , et al . 5-year versus risk-category-specific screening intervals for cardiovascular disease prevention: a cohort study [J]. Lancet Public Health , 2019 , 4 ( 4 ): e189 - e199 .
冯妍 , 冯奇 , 王以新 , 等 . 部分可观察马尔科夫决策过程优化不稳定型心绞痛中西医结合临床治疗方案的建模方法与验证研究 [J]. 中国全科医学 , 2020 , 23 ( 17 ): 2181 - 2185 .
庄杰钦 , 戴杏珍 , 金子淋 , 等 . 益气温阳活血利水法联合西医治疗急性心力衰竭疗效观察 [J]. 中华中医药杂志 , 2021 , 36 ( 2 ): 1153 - 1156 .
柏冬 , 岳广欣 , 王瑞海 , 等 . 基于Meta分析文献的5种中药注射剂治疗心力衰竭的临床使用特点 [J]. 中国中药杂志 , 2018 , 43 ( 20 ): 4152 - 4162 .
张岚 , 钱夕元 , 阮彤 . 基于Lasso的慢性心衰病人中西医疗效对比研究 [J]. 中国卫生统计 , 2019 , 36 ( 3 ): 365 - 367 .
朱文意 , 钱夕元 , 王英杰 , 等 . 中药对心衰住院病人的疗效分析:基于倾向值匹配法 [J]. 中国卫生统计 , 2018 , 35 ( 3 ): 420 - 422 .
孙洁 , 陈欣 . 沙库巴曲缬沙坦对不同病程的慢性心力衰竭患者的疗效评价 [J]. 临床心血管病杂志 , 2021 , 37 ( 10 ): 942 - 946 .
孙强 , 王宝英 , 王庆胜 , 等 . 院外多学科干预随访对慢性心力衰竭预后的影响 [J]. 临床心血管病杂志 , 2016 , 32 ( 9 ): 934 - 938 .
0
浏览量
3
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号